265312-91-2

Upstream product

• 100-39-0 benzyl bromide 
• 7464-56-4 1-O-allyl-α-D-glucopyranoside 
• 87326-31-6 1-O-allyl-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside 
• 103833-57-4 allyl 4,6-O-benzylidene-2,3-di-O-benzyl-α-D-glucopyranoside 
• 2280-44-6 D-Glucose 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 78184-40-4 1-O-allyl-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
• 98-59-9 p-toluenesulfonyl chloride 
• 93382-48-0 allyl 4,6-O-benzylidene-α-D-glucopyranoside 

Downstream Products

• 265312-93-4 1-O-allyl-2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranoside 
• 1105543-59-6 1-O-(2',3',4'-tri-O-benzyl-6'-thioacetyl-α-D-quinovosyl)propane-1,3-diol 
• 1234307-07-3 1-O-(2,3,4-tri-O-benzyl-6-sulfo-α-D-glucopyranosyl)propane-1,3-diol sodium salt 
• 1234307-08-4 C₄₁H₄₆NO₁₂S^(1-)*Na⁽¹⁺⁾ 
• 1105543-55-2 1-O-(2',3',4'-tri-O-benzyl-6'-O-tosyl-α-D-glucopyranosyl)propan-1,3-diol 
• 291297-64-8 Thioacetic acid S-[(2S,3S,4S,5R,6R)-3,4,5-tris-benzyloxy-6-(2,2,2-trichloro-acetimidoyloxy)-tetrahydro-pyran-2-ylmethyl] ester 
• 291297-63-7 Thioacetic acid S-((2S,3S,4S,5R,6S)-3,4,5-tris-benzyloxy-6-hydroxy-tetrahydro-pyran-2-ylmethyl) ester 
• 265312-97-8 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1,2-di-O-stearoyl-glycerol 
• 267900-43-6 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1,2-di-O-palmitoyl-glycerol 
• 338745-48-5 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1,2-di-O-myristoyl-glycerol 
• 338745-53-2 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1-O-stearoyl-glycerol 
• 267900-45-8 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1-O-palmitoyl-glycerol 
• 338745-49-6 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-1-O-myristoyl-glycerol 
• 265312-95-6 3-O-(2,3,4-tri-O-benzyl-6-deoxy-6-thioacetyl-α-D-glucopyranosyl)-glycerol 

Relevant academic research and scientific papers

Distribution and metabolism of 14C-sulfoquinovosylacylpropanediol (14C-SQAP) after a single intravenous administration in tumor-bearing mice

Sulfoquinovosylacylpropanediol (SQAP) is a novel potent radiosensitizer that inhibits angiogenesis in vivo and results in increased oxigenation and reduced tumor volume. We investigated the distribution, metabolism, and excretion of SQAP in male KSN-nude mice transplanted with a human pulmonary carcinoma, Lu65.For the metabolism analysis, a 2?mg (2.98?MBq)/kg of [glucose-U-14C]-SQAP (CP-3839) was intravenously injected. The injected SQAP was decomposed into a stearic acid and a sulfoquinovosylpropanediol (SQP) in the body.The degradation was relatively slow in the carcinoma tissue.1,3-propanediol[1-14C]-SQAP (CP-3635) was administered through intravenous injection of a 1?mg (3.48?MBq)/kg dose followed by whole body autoradiography of the mice.The autoradiography analysis demonstrated that SQAP rapidly distributed throughout the whole body and then quickly decreased within 4 hours except the tumor and excretion organs such as liver, kidney.Retention of SQAP was longer in tumor parts than in other tissues, as indicated by higher levels of radioactivity at 4 hours. The radioactivity around the tumor had also completely disappeared within 72 hours.

COMPOUND RETAINED IN TUMOR

A novel compound which specifically resides in a tumor, a method for allowing it to reside in a tumor, and a method for detecting, diagnosing, and treating tumor with use thereof are provided. The present invention relates to a compound represented by chemical formula (I) wherein R is an anionic group binding to hydrogen, R1 is OH, OCOH, OCO(CH2)hCH3, or an acting group, h being an integer of 0 or more, R2 is H, OH, OCOH, OCO(CH2)iCH3, or an acting group, i being an integer of 0 or more, R3 is OH, SO3H, or an acting group, R4 is OH, SO3H, or an acting group, and R5 is OH, SO3H, or an acting group, at least one of R1, R2, R3, R4, and R5 containing an acting group, or pharmaceutically acceptable salts thereof.

Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same

Sulfoquinovosylacyl propanediol compounds represented by formula (I): wherein R1 is an acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and M represents a cation having a positive charge equal to Y and pharmaceutically acceptable salts

Synthesis of sulfoquinovosylacylglycerols, inhibitors of eukaryotic DNA polymerase α and β

Sulfoquinovosyldiacylglycerols (SQDGs) and sulfoquinovosylmonoacylglycerols (SQMGs), bearing diverse fatty acids, were synthesized from d-glucose, and were examined for enzymatic inhibitions of DNA polymerase α and β. These results indicated that the carbon numbers of the fatty acids were highly related to the activities, at least in vitro, of eukaryotic DNA polymerase inhibition.

Structural determination of sulfoquinovosyldiacylglycerol by chiral syntheses

Chiral sulfoquinovosyldiacylglycerols (SQDGs) have been synthesized to determine the absolute stereochemistry and the biological activities. The 1 H NMR spectrum of a natural SQDG is comparable to that of synthetic (2S)-SQDG rather than that of the (2R) analogue. The biological activity of the respective isomers for DNA polymerase α and β inhibition was not distinguishable in the enzymatic assay.